The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Aug 30

PMID 32858953

Citations 2

Authors

Aaron L Magno

Lakshini Y Herat

Marcio G Kiuchi

Markus P Schlaich

Natalie C Ward

Vance B Matthews

Affiliations

Soon will be listed here.

Abstract

Studying the role of circulatory factors in the pathogenesis of diseases has been key to the development of effective therapies. We sought to examine the effect of antihypertensive therapies on numerous circulatory factors including short chain fatty acids and growth factors in a human cohort. A subset of participants from an earlier study was characterized by their hypertensive and/or treatment status and separated into three groups: (i) normotensives; (ii) untreated hypertensive and (iii) treated hypertensive subjects. Circulating levels of short chain fatty acids, FGF21 and TNF superfamily members were measured as part of this study. Both F2-isoprostane and circulating lipid levels were reanalysed as part of this current study. We found that antihypertensive treatment increased butyrate levels and decreased acetate levels to levels similar to normotensives. We also found that antihypertensive treatments reduced levels of circulating FGF21, TNFSF14 and TNF-α. In conclusion, we identified several circulatory factors that are altered in hypertension.

Citing Articles

TNFSF14/LIGHT promotes cardiac fibrosis and atrial fibrillation vulnerability via PI3Kγ/SGK1 pathway-dependent M2 macrophage polarisation.

Wu Y, Zhan S, Chen L, Sun M, Li M, Mou X J Transl Med. 2023; 21(1):544.

PMID: 37580750 PMC: 10424430. DOI: 10.1186/s12967-023-04381-3.

Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.

Li H, Zhou D, Gan R, Huang S, Zhao C, Shang A Nutrients. 2021; 13(9).

PMID: 34579087 PMC: 8470858. DOI: 10.3390/nu13093211.

References

Sacco R, Roth G, Reddy K, Arnett D, Bonita R, Gaziano T . The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation. Circulation. 2016; 133(23):e674-90. DOI: 10.1161/CIR.0000000000000395. View

Saunders B, Rudnicka C, Filipovska A, Davies S, Ward N, Hricova J . Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production. Immunol Cell Biol. 2018; 96(1):41-53. DOI: 10.1111/imcb.1002. View

Tan S, Caparros-Martin J, Matthews V, Koch H, OGara F, Croft K . Isoquercetin and inulin synergistically modulate the gut microbiome to prevent development of the metabolic syndrome in mice fed a high fat diet. Sci Rep. 2018; 8(1):10100. PMC: 6031638. DOI: 10.1038/s41598-018-28521-8. View

Yoshida S, Takeuchi T, Kotani T, Yamamoto N, Hata K, Nagai K . Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens. 2013; 28(3):165-9. DOI: 10.1038/jhh.2013.80. View

Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, SCHOLZE S, Burmester G . Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999; 34(1):113-7. DOI: 10.1161/01.hyp.34.1.113. View

Staiger H, Keuper M, Berti L, de Angelis M, Haring H . Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. Endocr Rev. 2017; 38(5):468-488. DOI: 10.1210/er.2017-00016. View

Mills K, Bundy J, Kelly T, Reed J, Kearney P, Reynolds K . Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016; 134(6):441-50. PMC: 4979614. DOI: 10.1161/CIRCULATIONAHA.115.018912. View

Matthews V, Elliot R, Rudnicka C, Hricova J, Herat L, Schlaich M . Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017; 35(10):2059-2068. DOI: 10.1097/HJH.0000000000001434. View

Beevers G, Lip G, OBrien E . ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001; 322(7291):912-6. PMC: 1120075. DOI: 10.1136/bmj.322.7291.912. View

10.

Shanmugam N, Figarola J, Li Y, Swiderski P, Rahbar S, Natarajan R . Proinflammatory effects of advanced lipoxidation end products in monocytes. Diabetes. 2007; 57(4):879-88. PMC: 2695452. DOI: 10.2337/db07-1204. View

11.

Dushay J, Chui P, Gopalakrishnan G, Varela-Rey M, Crawley M, Fisher F . Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139(2):456-63. PMC: 4862867. DOI: 10.1053/j.gastro.2010.04.054. View

12.

Jowett J, Okada Y, Leedman P, Curran J, Johnson M, Moses E . ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α. Immunol Cell Biol. 2012; 90(10):966-73. PMC: 3837706. DOI: 10.1038/icb.2012.44. View

13.

Wang W, Parchim N, Iriyama T, Luo R, Zhao C, Liu C . Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension. 2013; 63(3):595-606. PMC: 4053533. DOI: 10.1161/HYPERTENSIONAHA.113.02458. View

14.

Jin Q, Bando Y, Miyawaki K, Shikama Y, Kosugi C, Aki N . Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Invest. 2014; 61(1-2):28-34. DOI: 10.2152/jmi.61.28. View

15.

Robles-Vera I, Toral M, Duarte J . Microbiota and Hypertension: Role of the Sympathetic Nervous System and the Immune System. Am J Hypertens. 2020; 33(10):890-901. DOI: 10.1093/ajh/hpaa103. View

16.

Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J . FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018; 27(6):1323-1337.e5. DOI: 10.1016/j.cmet.2018.04.002. View

17.

Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G . Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol. 2003; 42(4):453-61. DOI: 10.1097/00005344-200310000-00001. View

18.

Bryhni B, Arnesen E, Jenssen T . Associations of age with serum insulin, proinsulin and the proinsulin-to-insulin ratio: a cross-sectional study. BMC Endocr Disord. 2010; 10:21. PMC: 3020169. DOI: 10.1186/1472-6823-10-21. View

19.

Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bachler J . Relationship between oxidative stress and essential hypertension. Hypertens Res. 2008; 30(12):1159-67. DOI: 10.1291/hypres.30.1159. View

20.

Zhu Y, Li Z, Ding A, Yang H, Zhu W, Cui T . Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice. Drug Des Devel Ther. 2019; 13:3657-3667. PMC: 6815789. DOI: 10.2147/DDDT.S217826. View